Cumberland Pharmaceuticals to acquire Theravance Biopharma’s Vibativ

Press enter to search
Close search
Open Menu

Cumberland Pharmaceuticals to acquire Theravance Biopharma’s Vibativ

By Sandra Levy - 11/09/2018
Specialty pharmaceutical company Cumberland Pharmaceuticals has reached an agreement to acquire Vibativ from Theravance Biopharma.

Vibatin (telavancin) is an anti-infective for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of gram-positive bacterial pathogens, including those that are considered difficult to treat and multidrug-resistant.

Cumberland will assume full responsibility for the product, including its marketing, distribution, manufacturing and regulatory activities.

"Vibativ is a lifesaving product for certain difficult to treat infections, and we are honored to be selected to acquire and transition the brand to our existing hospital acute care infrastructure," Cumberland Pharmaceuticals CEO A.J. Kazimi said. Our immediate plan for Vibativ is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion and medical initiatives to help ensure that the product is available to the patients who need it. We are very optimistic about the opportunity that Vibativ will offer Cumberland."

Related Topics